Literature DB >> 23946394

Serotonin 2A receptors differentially contribute to abuse-related effects of cocaine and cocaine-induced nigrostriatal and mesolimbic dopamine overflow in nonhuman primates.

Kevin S Murnane1, Jake Winschel, Karl T Schmidt, LaShaya M Stewart, Samuel J Rose, Kejun Cheng, Kenner C Rice, Leonard L Howell.   

Abstract

Two of the most commonly used procedures to study the abuse-related effects of drugs in laboratory animals are intravenous drug self-administration and reinstatement of extinguished behavior previously maintained by drug delivery. Intravenous self-administration is widely accepted to model ongoing drug-taking behavior, whereas reinstatement procedures are accepted to model relapse to drug taking following abstinence. Previous studies indicate that 5-HT2A receptor antagonists attenuate the reinstatement of cocaine-maintained behavior but not cocaine self-administration in rodents. Although the abuse-related effects of cocaine have been closely linked to brain dopamine systems, no previous study has determined whether this dissociation is related to differential regulation of dopamine neurotransmission. To elucidate the neuropharmacological and neuroanatomical mechanisms underlying this phenomenon, we evaluated the effects of the selective 5-HT2A receptor antagonist M100907 on intravenous cocaine self-administration and drug- and cue-primed reinstatement in rhesus macaques (Macaca mulatta). In separate subjects, we evaluated the role of 5-HT2A receptors in cocaine-induced dopamine overflow in the nucleus accumbens (n = 4) and the caudate nucleus (n = 5) using in vivo microdialysis. Consistent with previous studies, M100907 (0.3 mg/kg, i.m.) significantly attenuated drug- and cue-induced reinstatement but had no significant effects on cocaine self-administration across a range of maintenance doses. Importantly, M100907 (0.3 mg/kg, i.m.) attenuated cocaine-induced (1.0 mg/kg, i.v.) dopamine overflow in the caudate nucleus but not in the nucleus accumbens. These data suggest that important abuse-related effects of cocaine are mediated by distinct striatal dopamine projection pathways.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23946394      PMCID: PMC3742924          DOI: 10.1523/JNEUROSCI.1437-13.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  49 in total

1.  Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum.

Authors:  S N Haber; J L Fudge; N R McFarland
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

2.  Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior.

Authors:  Krista McFarland; Christopher C Lapish; Peter W Kalivas
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

3.  Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding.

Authors:  Paul J Fletcher; Andrew J Grottick; Guy A Higgins
Journal:  Neuropsychopharmacology       Date:  2002-10       Impact factor: 7.853

Review 4.  The validity of the reinstatement model of craving and relapse to drug use.

Authors:  Jonathan L Katz; Stephen T Higgins
Journal:  Psychopharmacology (Berl)       Date:  2003-04-15       Impact factor: 4.530

5.  Human midbrain dopamine neurons express serotonin 2A receptor: an immunohistochemical demonstration.

Authors:  K Ikemoto; A Nishimura; N Okado; M Mikuni; K Nishi; I Nagatsu
Journal:  Brain Res       Date:  2000-01-24       Impact factor: 3.252

6.  Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys.

Authors:  K M Wilcox; K P Lindsey; J R Votaw; M M Goodman; L Martarello; F I Carroll; L L Howell
Journal:  Synapse       Date:  2002-01       Impact factor: 2.562

7.  Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group.

Authors:  C Nocjar; B L Roth; E A Pehek
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

8.  3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement.

Authors:  William E Fantegrossi; Thomas Ullrich; Kenner C Rice; James H Woods; Gail Winger
Journal:  Psychopharmacology (Berl)       Date:  2002-04-19       Impact factor: 4.530

9.  Selective serotonin 2A receptor antagonism attenuates the effects of amphetamine on arousal and dopamine overflow in non-human primates.

Authors:  Kevin S Murnane; Monica L Andersen; Kenner C Rice; Leonard L Howell
Journal:  J Sleep Res       Date:  2013-10       Impact factor: 3.981

10.  Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue.

Authors:  Rutsuko Ito; Jeffrey W Dalley; Trevor W Robbins; Barry J Everitt
Journal:  J Neurosci       Date:  2002-07-15       Impact factor: 6.167

View more
  28 in total

1.  Development of translational preclinical models in substance abuse: Effects of cocaine administration on cocaine choice in humans and non-human primates.

Authors:  Richard W Foltin; Margaret Haney; Eric Rubin; Stephanie C Reed; Nehal Vadhan; Rebecca Balter; Suzette M Evans
Journal:  Pharmacol Biochem Behav       Date:  2015-04-28       Impact factor: 3.533

2.  Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.

Authors:  Laura Brandt; Jermaine D Jones; Suky Martinez; Jeanne M Manubay; Shanthi Mogali; Tatiana Ramey; Frances R Levin; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2020-01-17       Impact factor: 4.492

Review 3.  Modeling cocaine relapse in rodents: Behavioral considerations and circuit mechanisms.

Authors:  Mitchell R Farrell; Hannah Schoch; Stephen V Mahler
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-01-03       Impact factor: 5.067

4.  Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys.

Authors:  Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2016-05-27       Impact factor: 4.492

5.  Effects of a Serotonin 2C Agonist and a 2A Antagonist on Actigraphy-Based Sleep Parameters Disrupted by Methamphetamine Self-Administration in Rhesus Monkeys.

Authors:  Maylen Perez Diaz; Monica L Andersen; Kenner C Rice; Leonard L Howell
Journal:  Neuropsychopharmacology       Date:  2016-12-16       Impact factor: 7.853

6.  Repeated 7-Day Treatment with the 5-HT2C Agonist Lorcaserin or the 5-HT2A Antagonist Pimavanserin Alone or in Combination Fails to Reduce Cocaine vs Food Choice in Male Rhesus Monkeys.

Authors:  Matthew L Banks; S Stevens Negus
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

7.  The synthetic cathinone psychostimulant α-PPP antagonizes serotonin 5-HT2A receptors: In vitro and in vivo evidence.

Authors:  Yiming Chen; Bruce E Blough; Kevin S Murnane; Clinton E Canal
Journal:  Drug Test Anal       Date:  2019-04-22       Impact factor: 3.345

8.  Effects of acute treatments with the serotonin 2A antagonist M100907 alone or in combination with the serotonin 2C agonist WAY163909 on methamphetamine self-administration in rhesus monkeys.

Authors:  Melis Odabas-Geldiay; Hannah Shields; Lais F Berro; Kenner C Rice; Leonard L Howell
Journal:  Drug Alcohol Depend       Date:  2018-11-13       Impact factor: 4.492

9.  M100907 and BD 1047 attenuate the acute toxic effects of methamphetamine.

Authors:  Azizi Ray; Clinton E Canal; J Christopher Ehlen; Kenner C Rice; Kevin Sean Murnane
Journal:  Neurotoxicology       Date:  2019-06-01       Impact factor: 4.294

10.  Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys.

Authors:  Debra A Cooper; Heather L Kimmel; Daniel F Manvich; Karl T Schmidt; David Weinshenker; Leonard L Howell
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.